Macrocyclic peptides
OwnerJuan DEL VALLE, Benjamin Howard RAJEWSKI +1inventors
InventorsJuan DEL VALLE, Benjamin Howard RAJEWSKI, Kamlesh MAKWANA
Life of this patent
Estimating the term…
Loading patent…
OwnerJuan DEL VALLE, Benjamin Howard RAJEWSKI +1inventors
InventorsJuan DEL VALLE, Benjamin Howard RAJEWSKI, Kamlesh MAKWANA
Estimating the term…
Here, we describe a minimalist approach to mimic the aggregation-prone modules within tau. We carried out a backbone residue scan and showed that amide N-amination completely abolishes the tendency of these peptides to self-aggregate, rendering them soluble mimics of ordered β-strands from the tau R2 and R3 domains. Several N-amino peptides (NAPs) inhibit tau fibril formation in vitro. We further demonstrate that NAPs 12 and 13 are effective at blocking the cellular seeding of endogenous tau by interacting with monomeric or fibrillar forms of extracellular tau. Peptidomimetic 12 is serum stable, non-toxic to neuronal cells, and selectivity inhibits the fibrilization of tau over Aβ42. Structural analysis of our lead NAPs shows considerable conformational constraint imposed by the N-amino groups. The described backbone N-amination approach provides a rational basis for the mimicry of other aggregation-prone peptides that drive pathogenic protein assembly.
An N-amino peptide comprising a paired helical filament hexapeptide (PHF6) wherein one or more amino acid moieties of the PHF6 have an amide nitrogen atom along the hexapeptide backbone that is N-aminated, wherein the N-aminated amide nitrogen atom is hydrazide moiety NNH2.
Dependencies are inferred from the claim text.